41 results about "Meglumine" patented technology

The invention relates to the field of agricultural bactericides, in particular to a suspending agent containing fenaminstrobin and validamycin A and application of the suspending agent. The bactericidal composition comprises a suspending agent containing fenaminstrobin and validamycin A, an active component, a stabilizer, an auxiliary agent and water, the active component accounts for 1-70% of the mass of the preparation, and the stabilizer accounts for 0.1-10% of the mass of the preparation; wherein the active ingredients are fenaminstrobin and validamycin A, and the stabilizer is meglumine (N-methyl-D-glucosamine). The suspending agent prepared by the technical scheme of the invention effectively inhibits the increase of the particle size of a sample in the thermal storage process of a preparation, effectively improves the suspension rate of fenaminstrobin after the thermal storage of the preparation, improves the utilization rate of a pesticide, and ensures the normal exertion of the efficacy of the pesticide at the same time. Meanwhile, the quality of the active components of the stabilizer-containing bactericide is stable within the shelf life, the addition of the stabilizer does not cause the decomposition of the active components, and the preparation does not have obvious physical or chemical change.

This invention relates to an isosorbide dinitrate pharmaceutical composition injection and its preparation method. In addition to isosorbide dinitrate, the injection formulation also contains meglumine and glutathione. The preferred specifications are 5ml:5mg and 10ml:10mg. The isosorbide dinitrate injection prepared according to the formulation and process of this invention has the characteristics of high excipient safety, simple process, extremely high quality stability and good safety, which is significantly better than the prior art.

A composition for carbon dioxide (CO2) capture includes 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, meglumine, or combinations thereof. A process of CO2 capture includes mixing a CO2-containing gas with the composition. A system includes a component for receiving a gas and the composition, which absorbs CO2 from the gas. A further composition includes a first amine solvent selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, and meglumine and a second amine solvent independently selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, meglumine, ethyl diethanolamine, dimethylethanolamine, piperidine, 2-amino-2-methyl-1-propanol, and monoethanolamine. A further process includes reacting CO2 with an amine selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, and meglumine.

This invention discloses a meglumine-luteolin complex, its preparation method, and its applications, belonging to the interdisciplinary field of microbiome and drug delivery. Using luteolin as the main material, this invention employs a dual inclusion technique with hydroxypropyl-β-cyclodextrin and meglumine to synergistically prepare a meglumine-luteolin complex with colon-targeted delivery capabilities. This invention significantly improves the delivery efficiency and drug loading of luteolin in the colon through the dual inclusion technique. The preparation process is simple, and it exhibits excellent hypoglycemic effects and colon-targeted release characteristics in the treatment of diabetes and its complications.

Salts of R-ketorolac, including solid salts, such as crystalline salts of the meglumine and tromethamine salts R-ketorolac, are disclosed. Methods of preparing such salts, pharmaceutical compositions comprising salts, and methods of treating cancer with such salts are further provided.

The invention provides a crystal form of a compound HIF-117 salt as well as a preparation method and application of the crystal form, and the crystal form is any one or more of the following crystal forms: a hydrochloride crystal form A, a sulfate crystal form B, a 1, 2-ethanedisulfonate crystal form C1, 1, 2-ethanedisulfonate crystal form C2, 1, 2-ethanedisulfonate crystal form C3 and 1, 2-ethanedisulfonate crystal form C4. The crystal form 1, 2-ethanedisulfonate crystal form C2, p-toluenesulfonate crystal form D, mesylate crystal form E1, mesylate crystal form E2, hydrobromide crystal form F1, hydrobromide crystal form F2, sodium salt crystal form G, sylvite crystal form H1, sylvite crystal form H2, calcium salt crystal form I, magnesium salt crystal form J, choline salt crystal form K, lysine salt crystal form L, ammonium salt crystal form M, meglumine salt crystal form N, betaine salt crystal form O1, betaine salt crystal form O2 and diethylamine salt crystal form P1, the invention relates to a diethylamine salt crystal form P1, a diethylamine salt crystal form P2, a diethylamine salt crystal form P3, a diethylamine salt crystal form P4, a diethylamine salt crystal form P5, a tromethamine salt crystal form Q1, a tromethamine salt crystal form Q2 and a tromethamine salt crystal form Q3. The compound has good stability, and has important value for development and production of medicines and preparations.

The utility model relates to the field of medical product processing, in particular to concentration equipment for processing meglumine chlorzolate, which comprises a mounting rack, a concentration tank and a storage tank, the concentration tank is fixed on one side in the mounting rack, a plurality of filtering holes are arranged at the bottom in the concentration tank, and the storage tank is fixed on the other side in the mounting rack. A discharge hopper is arranged at the bottom of the concentration tank corresponding to the outside of the filter-out hole, an electric heating tube with a wiring end extending to the outside is mounted between the bottom in the discharge hopper and the outside of the concentration tank, and the discharge hopper and the bottom of the storage tank are both communicated with a discharge tube. The vacuum pump is used for creating a low-pressure environment, the boiling point of a solvent is reduced, low-temperature evaporation is realized, and the concentration efficiency is greatly improved; through a heating, stirring, condensing and pressure monitoring system which is accurately controlled by an electric heating tube, a motor, a bevel gear and a condenser, the stability of the whole concentration process is ensured, and the quality fluctuation is reduced; safety parts such as a check valve and a pressure gauge can improve safety of the system, and backflow and overpressure risks are prevented.

The application discloses an arylpropionic acid non-steroidal anti-inflammatory drug preparation composition and a preparation method thereof. The composition is a solution preparation or a gel paste preparation containing arylpropionic acid non-steroidal anti-inflammatory drugs, and is characterized by containing arylpropionic acid non-steroidal anti-inflammatory drugs or isomers thereof and pharmaceutically acceptable solvents and adjuvants such as propylene glycol; wherein the mass / volume percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the solution preparation ranges from 1 mg / ml to 40 mg / ml, and the volume percentage of the propylene glycol ranges from 50% to 100%; the mass percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the gel paste preparation ranges from 1% to 10%, and the mass percentage of the propylene glycol ranges from 5% to 12%. The arylpropionic acid non-steroidal anti-inflammatory drugs in the prescription are in RS-configuration or derivatives, R-configuration or derivatives, S-configuration or derivatives, or a combination of the R-configuration or derivatives and the S-configuration or derivatives in any ratio; and the pH regulator is one or more of lysine, arginine, tromethamine, meglumine and the like.

The invention belongs to the technical field of capsule preparations, and relates to a plant starch soft capsule and a preparation method thereof. The plant starch soft capsule is prepared from hydroxypropyl starch, carrageenan, plantain seed gum, sodium alginate, sodium hyaluronate and meglumine. The preparation method comprises the steps of raw material pretreatment, mixing and glue preparation, vacuum degassing, soft capsule forming and drying. Through the innovative raw material ratio and preparation process, the soft capsule has excellent weather resistance and can adapt to transportation and storage at extreme temperature; meanwhile, the product is mainly prepared from plant source raw materials, so that the fishy smell caused by gelatin is eliminated, and the use comfort and the market acceptability are improved. The plant starch soft capsule can be applied to the field of cosmetics and used as a carrier of active ingredients.

The present invention relates to a liquid pharmaceutical composition comprising (i) totally dissolved tretinoin or a pharmaceutically acceptable isomer thereof; (ii) d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS); (iii) a pH-modifying agent selected in the group consisting of meglumine, potassium hydroxide (KOH), sodium hydroxide (NaOH), sodium acetate (anhydrous, trihydrate, and mixtures thereof), potassium acetate (anhydrous, trihydrate, and mixtures thereof), di-potassium hydrogenophosphate, di-sodium hydrogenophosphate, tri-sodium phosphate, tri-potassium phosphate, and mixtures thereof; and (iv) water. The present invention also relates to the medical uses of such a composition.

The application discloses a super-long chain glucose amide nonionic surfactant and a synthesis method thereof. The hydrophobic tail chain of the surfactant is derived from plant-based fatty acids such as oleic acid, erucic acid or nervonic acid, and the hydrophilic head group is derived from glucose derivatives such as meglumine and glycolglucamine. With oleic acid, erucic acid and nervonic acid in rapeseed by-product as hydrophobic tail chain raw material, glucose derivatives meglumine and glycolglucamine as hydrophilic head group raw material, methanol, ethanol, ethylene glycol or propylene glycol (single solvent or binary mixed solvent) as solvent, and DMAP or NaF as catalyst, a kind of bio-based surfactant is obtained. The super-long chain glucose amide nonionic surfactant is prepared by selective amination reaction, the hydroxyl group in the glucose amine molecule does not need to be protected complicatedly, the reaction temperature is close to room temperature, the operation is simple, and the purification process only needs a simple industrial crystallization method, which is suitable for industrial production.

The present disclosure provides meglumine salts of CX3CR1 modulators, polymorphs and pharmaceutical compositions thereof. Also disclosed are methods of treatment using the meglumine salts of CX3CR1 modulators, polymorphs and pharmaceutical compositions thereof and methods of making salt compounds of CX3CR1 modulators and polymorphs thereof.

A method produces an aqueous liquid preparation for magnetic resonance contrast that contains a complex of a lanthanide and a macrocyclic chelate together with free chelate. A solution of the macrocyclic chelate in water is prepared, lanthanide and meglumine are added, and complex formation proceeds in the presence of meglumine at a pH between 6.5 and 8.0 with lanthanide in molar excess over meglumine and meglumine in molar excess over the chelate. The pH is then reduced to a target value below 5.0 by incremental addition of an acid such as further chelate, optionally followed by addition of a fixed chelate amount. The pH is subsequently raised above 6.5 with meglumine and the solution is diluted to a final volume, providing an industrial-scale single-vessel process that yields a preparation containing a defined low amount of free lanthanide.

The application provides a sustained-release meglumine microtablet, which is composed of a sustained-release layer, a release layer and a coating layer, the sustained-release layer and the release layer form a double release system, and the release speed of the meglumine is effectively controlled by controlling the drug proportion of the sustained-release layer and the release layer, so that the problem of fast drug release caused by small volume and large specific surface area of the microtablet is solved, and the microtablet realizes long-time and sustained and stable drug release. The meglumine sustained-release microtablet provided by the application has a diameter of 1-3 mm and a tablet weight of 20-60 mg, compared with common tablets, the sustained-release microtablet can reduce the drug administration frequency of patients, realizes once-a-day drug administration, improves the compliance of patients, and can meet the drug administration needs of children, the elderly and patients with dysphagia and the like.

The application belongs to the technical field of medicine, and particularly relates to a ketoprofen in-situ co-amorphous composition. The co-amorphous composition is composed of ketoprofen, lysine, arginine and meglumine, and can spontaneously form a homogeneous disordered arrangement when contacting with an aqueous medium (including a dissolution process). Through powder X-ray diffraction, differential scanning calorimetry and Fourier infrared spectroscopy analysis, the three compositions can be co-amorphized in-situ when contacting with a trace amount of aqueous medium or in a dissolution process, so that the solubility and dissolution rate of ketoprofen are significantly improved, and the oral absorption and therapeutic effect of ketoprofen are expected to be enhanced. Meanwhile, the degree of in-situ co-amorphization is closely related to the molar ratio of the composition, the contacting time, the pH and the temperature of the medium. The application mediates the occurrence of in-situ co-amorphization of ketoprofen through prescription composition and design, improves the solubility and dissolution defects of the drug, and provides a new preparation idea.

The invention belongs to the technical field of organic synthesis, and particularly relates to a synthetic method of meglumine. The method comprises the following steps: 1) dissolving glucose and methylamine in water to prepare a reaction solution; 2) adding a catalyst into the reaction liquid for reaction; and 3) after the reaction is finished, filtering and separating the catalyst, and carrying out post-treatment on the reaction liquid to obtain the meglumine. On the basis of mature reductive amination reaction, a green and environment-friendly water phase system and an efficient heterogeneous catalysis path are selected, high efficiency and high selectivity of product conversion are achieved by means of the structural advantage of the hierarchical porous Ni / SiO2-Hier catalyst and the requirement high matching capacity of a reaction system, and the method has the synthesis advantages of being green and efficient.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a celecoxib tablet and a preparation method thereof.The celecoxib tablet is composed of celecoxib, lactose-microcrystalline cellulose compounded according to a specific proportion, polyvinylpolypyrrolidone-carboxymethyl starch sodium, a lubricant and a solubilizing stabilizer. Wherein the solubilizing stabilizer is beta-cyclodextrin, sodium stearoyl lactylate and meglumine. The preparation method comprises the steps of pretreatment of the celecoxib and the solubilizing stabilizer, step-by-step granulation, drying and size stabilization, and total mixing and tabletting. Through the synergistic effect of the compound solubilizing stabilizer and the wet grinding process and in combination with the preparation method of step-by-step mixing granulation, the content uniformity, the dissolution performance and the storage stability of the prepared celecoxib tablet are remarkably improved, and the preparation process is simple and easy to operate and suitable for industrial large-scale production.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an oxaliplatin-containing microcapsule and a preparation method thereof. The microcapsules are prepared from the following components in parts by weight: 50 parts of oxaliplatin, 5 to 10 parts of meglumine, 1 to 5 parts of lacrotitol, 34.5 to 56.8 parts of Arabic gum, 15 to 33 parts of L-proline, 3.5 to 5.5 parts of polyethylene glycol 6000 and 4 to 8 parts of polyvinyl alcohol-polyethylene glycol grafted copolymer; the capsule material and the content of the capsule material are optimized, the encapsulation efficiency and the yield are remarkably improved, and the finally prepared preparation is relatively low in content of related substances, can be stored and applied for a long time and has a very good development value.

The application provides a fast-acting flunixin meglumine injection and a preparation method thereof, and belongs to the technical field of veterinary medicine, and contains the following components: flunixin meglumine 5-10 (w / v) %, alpha-pyrrolidone 10-30 (w / v) %, hydrophilic solvent 0.5-1 (w / v) %, antioxidant 0.1-0.3 (w / v) % and the balance of water for injection. The application takes flunixin meglumine as the main drug, matches alpha-pyrrolidone as a solvent and a targeting guide distribution component, uses a hydrophilic solvent to assist dissolution and promote absorption, and uses an antioxidant to inhibit the oxidative degradation of the main drug, so that the dissolution and absorption rate of the main drug and the target tissue distribution efficiency can be effectively improved, the storage stability can be ensured, the bacterial endotoxin and the injection site redness rate meet the requirements, the acute inflammation and pain of livestock and poultry can be quickly and efficiently relieved, and the demand for instant intervention in large-scale breeding can be met.

The application belongs to the technical field of medicine, and particularly discloses a small-molecule indometacin hydrogel and a preparation method thereof. The small-molecule hydrogel is obtained by mixing indometacin and a small-molecule ligand, adding a small amount of deionized water, and oscillating. The small-molecule hydrogel has the advantages of solubility and permeability, with the small-molecule ligand as a matrix. The formed small-molecule hydrogel can significantly improve the solubility and dissolution / release rate of indometacin. Compared with indometacin crystals, the water solubility of the two small-molecule hydrogels of indometacin-meglumine and arginine is increased by 506 times and 479 times, respectively, and the cumulative release rate at 2h is increased by 2.67 times and 3.05 times, respectively. Meanwhile, the small-molecule hydrogel significantly promotes the membrane permeability of indometacin, enhances the development potential of indometacin in oral and transdermal applications, and provides a new preparation idea for solving the solubility and permeability defects of non-steroidal anti-inflammatory drugs and other poorly soluble drugs.

The invention discloses a pharmaceutical composition containing linagliptin and metformin hydrochloride and a preparation method thereof.According to the composition, a small amount of meglumine (0.01%-1.0% w / w) is added, a linagliptin mixture and a metformin hydrochloride mixture are separately granulated, the growth of an impurity A, an impurity B and total impurities in an obtained linagliptin and metformin hydrochloride tablet is slow, the content of impurities in the linagliptin and metformin hydrochloride tablet is low, and the content of impurities in the linagliptin and metformin hydrochloride tablet is high. The stability of the composition is obviously improved, and the dissolution effect is not influenced. According to the preparation method of the composition, auxiliary materials in the preparation process are easy to obtain, the price is low, and the composition is suitable for commercial production.

The present invention is related to a novel pharmaceutical product containing iron and meglumine. In certain embodiments, the present invention is related to a novel injectable dosage form comprising ferric meglumine as a parenteral iron supplement to treat iron deficiency anemia. In certain embodiments, the present invention is related to a novel oral dosage form comprising ferric meglumine as iron supplement and / or phosphate binder.

The present application belongs to the technical field of capsule preparation, and relates to a plant starch soft capsule and a preparation method thereof. The plant starch soft capsule is composed of hydroxypropyl starch, carrageenan, psyllium seed gum, sodium alginate, sodium hyaluronate and meglumine. The preparation method comprises the steps of raw material pretreatment, mixing and gel preparation, vacuum degassing, soft capsule forming and drying. Through innovative raw material ratio and preparation process, the soft capsule has excellent weather resistance, can adapt to transportation and storage under extreme temperature, and is mainly made of plant-derived raw materials, so that the fishy smell caused by gelatin is eliminated, and the use comfort and market acceptance are improved. The plant starch soft capsule can be applied to the field of cosmetics and used as a carrier of active ingredients.

The method for improving the moisture resistance of the silybin meglumine tablet comprises the following steps: S1, tablet core pretreatment: screening and surface treatment are performed on the silybin meglumine tablet core; s2, preparing a coating solution: sequentially adding a film coating material, a plasticizer and a pore-foaming agent into a solvent, and stirring and mixing to obtain the coating solution; s3, coating: putting the screened tablet cores into a rotating pan of a coating machine, starting the coating machine to rotate the tablet cores, and attaching a coating solution to the surfaces of the tablet cores by spraying, so that the coating solution forms a coating film on the surfaces of the tablet cores; and S4, coating post-treatment: carrying out aging treatment on the coated silybin meglumine tablets, and stabilizing a coating film. According to the method disclosed by the invention, the coating film is attached to the surface of the silybin meglumine tablet, so that the aims of preventing moisture, guaranteeing the drug effect and improving the coating quality are fulfilled.

The present application relates to a kind of carboprost tromethamine injection and its preparation method.The injection uses meglumine as pH regulator, not only stable to CO2 in environment, and it is beneficial to improve the stability of carboprost tromethamine;At the same time, pre-charged needle injection is also avoided the operation of ampoule sealing, so that the prepared carboprost tromethamine injection can be stored at 2~20 ℃, storage and transportation and clinical use are more convenient.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to cefixime granules and a preparation method thereof. The cefixime granules provided by the invention are prepared from cefixime, a dissolution-promoting and stability-maintaining agent and pharmaceutically acceptable auxiliary materials, wherein the dissolution-promoting and stability-maintaining agent is a combination of sodium caprylate and meglumine; meanwhile, the dissolution-promoting stability-maintaining agent and the cefixime are subjected to a specific pretreatment process, and then the cefixime particles are prepared through a wet granulation process. According to the technical scheme, the dissolution performance and the stability of the cefixime granules are synergistically optimized, and the preparation process is simple, convenient and controllable, does not need to depend on a special high-energy-consumption process, has relatively high industrial feasibility and is beneficial to large-scale production and market promotion.

The invention relates to the field of biological medicine preparations, and particularly discloses compound amoxicillin powder and a preparation process thereof. The compound amoxicillin powder is prepared from the following raw material components in parts by weight: 100 parts of amoxicillin; 15 to 18 parts of potassium clavulanate; 400 to 420 parts of lipid; 6-8 parts of a stabilizer; 0.4 to 0.5 part of a meglumine surfactant; the lipid comprises soybean lecithin and cholesterol in a weight ratio of (3.8-4): 1; the preparation method comprises the following steps: S1, blending the amoxicillin and the lipid to obtain the amoxicillin liposome; s2, dispersing the amoxicillin liposome and a meglumine surfactant in water, stirring, adding a stabilizer, stirring, filtering, freeze-drying, and blending with potassium clavulanate to obtain the compound amoxicillin powder. The compound amoxicillin powder disclosed by the invention has relatively high bioavailability, does not need to be frequently administered to an organism, and is relatively high in practicability and good in drug effect.

The invention discloses a preparation method of gadotec acid meglumine. The gadotec acid meglumine is prepared by taking DOTA, gadolinium oxide and meglumine as raw materials. Wherein the related substances in the DOTA meet the following conditions in percentage by mass: less than or equal to 0.05% of impurity RM, and / or less than or equal to 0.05% of impurity P01, less than or equal to 0.05% of impurity P02, less than or equal to 0.05% of impurity P03, less than or equal to 0.05% of impurity P04 and less than or equal to 0.5% of total impurities. The invention also relates to the bulk drug prepared by the preparation method and a high performance liquid chromatography detection method thereof. On the basis of deep research, according to consideration factors such as the importance degree of each quality index and / or the difficulty degree of removing one or some impurities, key process conditions or parameters for preparing gadadotec acid meglumine are finally found out and determined; product quality management and / or control of the production source and even the whole process of the gadadotec acid meglumine bulk drug are / is really realized and strengthened, and the medication safety of vast patients is better guaranteed.

Disclosed for the first time are a pyrimidine derivative meglumine salt as shown below and crystal forms thereof. A series of the crystal forms exhibits good developability (such as stability, fluidity, compressibility, solubility, bioavailability, etc.), providing a variety of bulk drug options for subsequent drug development.

The application relates to the technical field of medicines, in particular to an icotinamide tablet of icotinib and a preparation method thereof; the icotinamide tablet of icotinib comprises the following components: icotinamide, an amphiphilic carrier, a microenvironment regulator and pharmaceutically acceptable adjuvants, wherein the mass ratio of the icotinamide, the amphiphilic carrier and the microenvironment regulator is 1:(1-3):(0.5-1.5), the amphiphilic carrier is Soluplus, and the microenvironment regulator is meglumine; the application discloses an icotinamide tablet of icotinib and a preparation method thereof; the three components of icotinamide, the amphiphilic carrier Soluplus and the microenvironment regulator meglumine are ground together, the solubility and the dissolution of the medicine in a high-calcium medium can be effectively improved, the postprandial bioavailability is increased, and the stability is good.